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Abstract
MicroRNAs  play  important  roles  in  many  biological  processes.  Their  aberrant
expression can have oncogenic or tumor suppressor function directly participating to
carcinogenesis,  malignant  transformation,  invasiveness  and  metastasis.  Indeed,
miRNA profiles can distinguish not only between normal and cancerous tissue but
they can also successfully classify different subtypes of a particular cancer.
Here,  we focus on a particular class of transcripts  encoding polycistronic miRNA
genes  that  yields  multiple  miRNA  components.  We  describe  clustered  MiRNA
Master Regulator Analysis (ClustMMRA), a fully redesigned release of the MMRA
computational pipeline (MiRNA Master Regulator Analysis), developed to search for
clustered  miRNAs  potentially  driving  cancer  molecular subtyping.  Genomically
clustered miRNAs are frequently co-expressed to target different components of pro-
tumorigenic signalling pathways. By applying ClustMMRA to breast cancer patient
data,  we  identified  key  miRNA clusters  driving  the  phenotype  of  different  tumor
subgroups. The pipeline was applied to two independent breast cancer datasets,
providing statistically concordant results between the two analysis. We validated in
cell lines the miR-199/miR-214 as a novel cluster of miRNAs promoting the triple
negative subtype phenotype through its control of proliferation and EMT.
1. Introduction
MicroRNAs (miRNAs) are small RNA molecules emerged as important regulators of
gene  expression  at  the  post-transcriptional  level.  They  have  been  shown  to  be
involved in the regulation of all essential functions of the cells from differentiation and
proliferation to apoptosis1. Each miRNA possesses hundreds of target genes, and a
single gene can be targeted by several miRNAs2, giving rise to complex interaction
networks, currrently very partially characterized.
Multiple studies demonstrated the importance of miRNAs in all the cancer hallmarks
defined  by  Hanahan  and  Weinberg3 and  indicated  that  they  might  function  as
oncogenes or tumor suppressors4–7. Further experimental evidences suggested that
specific  miRNAs  may  also  have  a  role  beyond  the  cancer  onset  and  directly
participate  in  cancer  invasiveness and metastasis6,8.  Indeed,  miRNA profiles  can
distinguish  not  only  between  normal  and  cancerous  tissue  but  they  can  also
successfully classify different subtypes of a particular cancer9,10,  notably of breast
cancer11–13. 
In  this  work,  we  focused our  attention  on  a  particular  class  of  transcripts
encoding  polycistronic  miRNA genes  that  yields  multiple  miRNA components.  A
famous example of this class of transcripts is the mir-17/92 polycistronic oncogene
that plays a role in the development of various cancer types, especially in their most
aggressive form14.  Genomically clustered miRNAs of mir-17/92 are simultaneously
expressed and target different components of the signaling cascade as well as the
downstream effectors of pro-tumorigenic signalling pathways15–17. Deep sequencing
of triple negative breast cancer (TNBC) samples revealed a threefold increase of
miR-17/92 levels12.  Other  studies  in  breast  cancer  have  shown that  mir-106b/25
cluster activates TGF-β signaling and epithelial-mesenchymal transition (EMT)18 and
miR-221/222 cluster is a key regulator of luminal breast cancer tumor progression19. 
 Since more than 30% of annotated human miRNAs are organized in genomic
clusters, we can expect to find other oncogenic / tumour suppressor polycistronic
miRNAs that  are co-expressed to jointly regulate molecular pathways involved in
cancer  malignancy.  Existing  computational  approaches  for  the  identification  of
master  miRNA  regulators  involved  in  cancer  onset  and  subtyping  are  typically
designed to detect the effect of a single miRNA (see review in20). However, miRNAs
have been shown to frequently act in a combined manner, jointly regulating proteins
in close proximity of the protein-protein interaction network21 and functionally related
genes22–25. The underlying assumption of this work is that this mode of action might
be true also for genomically clustered miRNAs. Indeed, it has already been shown
that clustered miRNAs carry out pervasive cotargeting26.
Here we present Clustered MiRNA Master Regulator Analysis (ClustMMRA), a fully
redesigned release of the  MiRNA Master Regulator Analysis (MMRA)25,26 pipeline,
developed  to  search  for  clustered  miRNAs  potentially  driving  cancer  subtyping.
MMRA  was  designed  for  miRNA  underlying  tumor  subtypes,  a  comparison
characterized by much lower variation than cancer versus normal conditions. The
results of the MMRA pipeline were experimentally validated, proposing a set of four
miRNAs predicted to drive the stem-like aggressive colorectal cancer subtype27.
ClustMMRA extends MMRA to a model in which multiple miRNAs belonging to the
same  genomic  cluster  coordinately  target  functionally  related  genes  driving  the
phenotype of a particular cancer subtype. As the MMRA pipeline, ClustMMRA is a
multi-step  workflow that  requires  in  input  miRNA/mRNA expression  profiles  from
matched tumor samples classified in different subtypes according to subtype-specific
gene  signatures.  The  final  output  of  ClustMMRA  provides  key  miRNA  clusters
contributing to the regulation of particular subtypes of the disease.
We  tested  this  novel  pipeline  to  search  for  oncogenic  /  tumour  suppressor
polycistronic miRNAs driving breast cancer subtypes. ClustMMRA was applied to
two independent breast cancer datasets whose samples were previously classified
into four subtypes (luminal A, luminal B, HER2+ and triple negative). We obtained
statistically concordant results between the two analysis, identifying five clusters of
miRNAs with aberrant  expression in a specific subtype of both datasets.  Among
them, miR-199a/214 on chromosome 1 was found to be down-regulated in the triple
negative subtype and associated to EMT regulation. Functional validation in cell lines
confirms the regulatory effect of this cluster in shaping the triple negative subtype
phenotype through its control of proliferation and EMT. Overall, our computational
pipeline and experimental validations characterize a new genomic cluster of miRNAs
implicated in the TNBC phenotype that might be further explored in diagnosis and
therapeutic  strategies.  In  addition,  we  evinced  a  cooperative  mechanism for  the
regulatory activity of genomically clustered miRNAs.
2. Results
2.1 From single miRNA to clusters of miRNAs: ClustMMRA
The MMRA pipeline is here extended to search for genomically co-clustered miRNAs
potentially driving cancer subtyping. Similar to  MMRA, the workflow of ClustMMRA
(see  Figure  1)  consists  of  subsequent  filtering  steps:  (i)  differential  expression
analysis  of  clustered  miRNAs;  (ii)  target  enrichment  analysis  and  (iii)  network
analysis.  While  a  miRNA cluster  is  usually  transcribed  as  a  single  unit28–32,  the
expression of mature miRNAs in the same cluster might not be highly correlated due
to regulatory events in the maturation processes28,31. 
Clusters of miRNAs are identified based on their genomic organization as reported in
Methods. In step (i), the subtype-specific expression of each miRNA is assessed by
Kolmogorov-Smirnov (KS) statistical test and fold change cutoff. Clusters having at
least  two miRNAs with subtype-specific expression change in the same direction
(both up-regulated or down-regulated) are selected for step (ii). 
In step (ii), we extract miRNA clusters having their predicted targets enriched for the
gene signature of the corresponding subtype. Only miRNAs of the cluster classified
as  differentially  expressed  in  step  (i)  are  considered  in  step  (ii).  The  targets  of
individual miRNAs have been predicted using four different databases (miRTarBase
2.5,  doRiNA-PicTar  2012,  microRNA.org  2010,  PITA 2007 and  TargetScan 7.1),
requiring the prediction by at least two of them. The set of targets of a cluster has
been defined as the union of the targets of individual miRNAs. The objective of step
(i) and (ii) is to identify co-clustered and co-expressed miRNAs potentially regulating
a gene expression signature in a joint manner, without necessarily having a high
overlap in terms of target genes23. Finally, in step (iii) a miRNA-mRNA interaction
network is constructed for each selected cluster using the ARACNE algorithm33,34. In
this  step,  we  identify  modules  of  co-clustered  miRNAs  and  interacting  genes,
including indirect interactions, that are believed to participate in the phenotype of a
given cancer subtype (we call  these modules  regulons).  Unlike the results of the
MMRA pipeline, in which regulons can include only one miRNA, the ones identified
by  the  ClustMMRA  pipeline  contain  multiple  miRNAs  of  the  genomic  cluster.
Interference  of  indirect  interactions  may  introduce  links  between  miRNAs  and
spurious genes in the regulon. A Fisher’s exact test has been performed to evaluate
the statistical significance of the overlap between the genes included in each regulon
and the gene signature of the associated subtype.
2.2  Identification  of  regulatory  miRNA  clusters  underlying  breast  cancer
subtypes
We applied ClustMMRA to identify polycistronic miRNAs underlying breast cancer
molecular  subtypes.  For  this  study,  two independent  datasets  were  used,  a  first
paired  miRNA/mRNA  expression  dataset  from  a  in-house  cohort of  129  breast
carcinoma tumour samples (which we refer to as  Curie dataset35,36 and a second
dataset from The Cancer Genome Atlas project composed of 397 samples37. In both
datasets, individual samples were assigned to four subtypes (luminal A, luminal B,
HER2+ and triple negative) based on the immunohistochemical staining of estrogen
(ER), progesterone (PR) and HER-2 (ERBB2) receptors.
2.2.1 ClustMMRA application to Curie and TCGA datasets
Expression data required for running ClustMMRA were pre-processed as described
in Methods and the signatures for breast cancer subtypes were defined using the
approach  proposed  in38 (see  Methods).  We  applied  the  ClustMMRA pipeline  on
Curie  and  TCGA datasets  separately.  In  the  first  step,  genomically  co-clustered
miRNAs having a subtype-specific expression were identified. In this step, 28 and 47
out of 131 analyzed clustered miRNAs were selected for Curie and TCGA datasets,
respectively (see Supplementary Table S1). Of these, 18 clusters were in common
between  the  two  datasets  (p-value<7e-04),  revealing  a  significantly  concordant
expression  pattern  of  co-clustered  miRNAs.  Among  these  co-clustered  and  co-
expressed miRNAs, some are differentially expressed in multiple subtypes (18 and
37 clusters for  Curie and TCGA respectively), with 15 out of 18 and 21 out of 37
differentially expressed in basal-like and luminal A with opposite sign. 
In step (ii), 10 out of 28 (Curie) and 16 out of 47 (TCGA) subtype-specific miRNA
clusters were found to have their predicted targets enriched in genes belonging to
the corresponding gene signature. The output of step (ii) (see Supplementary Table
S2) has an intersection of 7 elements between the two datasets (p-value <1e-05). In
the step (iii) of ClustMMRA, a  regulon for each miRNA cluster selected in step (ii)
was constructed. The regulons were tested for enrichment in gene signature. 7 out of
10  and 9 out  of  16  clusters  passed this  last  selection  step  in  Curie  and TCGA
datasets, respectively. These clusters constitute the final output of ClustMMRA and
are reported in Table 1. After this last step, the output in common between the two
datasets  contains  5  clusters  (p-value  <8e-06).  The  significant  overlap  between
results  obtained from the  analysis  of  two independent  datasets  with  ClustMMRA
supports the reliability of this approach. Notably, the results have an intersection with
increasing statistical significance at each step of the pipeline. This trend confirms the
accuracy of the proposed pipeline in selecting candidate clusters underlying cancer
subtypes. 
Some results obtained with ClustMMRA in the breast cancer study have already
been  validated  in  the  literature.  MiR-493/136  and  miR-379/656  clusters  in  the
chromosomal region 14q32 have been reported as tumor suppressors in different
types of human cancer39–41, including breast cancer42. Silencing of multiple miRNAs
encoded in these clusters was shown to increase the proliferation and invasion of
ovarian  43,  melanoma44 or  oral  squamous carcinoma39 cells.  The X-chromosome-
located miR-532/502 cluster has been previously associated to cancer. In particular,
this was found up-regulated in triple-negative breast cancer cells45 and the regulatory
circuit miR-502/H4K20 methyltransferase SET8 was described as a key regulator of
breast cancer pathobiology46. 
Table 1. Clusters of miRNAs identified by ClustMMRA in breast cancer TCGA
and/or Curie datasets.
Cluster of
miRNAs
Chromosome
position
Number of
deregulated
miRNAs in the
cluster
Cluster
expression in
subtypes
Gene signature
expression 
in subtypes
Dataset results
miR-199a/214 Chr1 3 Down in 
Basal-like
Up in Basal-like Curie and TCGA
miR-493/136 Chr14 8 Down in 
Basal-like
Up in Basal-like Curie and TCGA
miR-379/656 Chr14 42 Down in 
Basal-like
Up in Basal-like Curie and TCGA
miR-512/373 Chr19 46 Up in Basal-like Up in Basal-like Curie and TCGA
miR-532/502 ChrX 8 Up in Basal-like Down in Basal-like Curie and TCGA
miR-449a/449c Chr5 3 Down in 
Basal-like
Down in Basal-like TCGA
miR-653/489 Chr7 2 Down in 
Basal-like
Down in Basal-like TCGA
miR-548aa/548d Chr8 2 Up in Basal-like Down in Basal-like TCGA
miR-421/374c ChrX 3 Up in Basal-like Up Basal-like TCGA
miR-99a/let-7c Chr21 2 Down in 
Basal-like
Up Basal-like Curie
miR-450b/424 ChrX 6 Down in 
Basal-like
Up Basal-like Curie
2.2.2  Comparison  of  ClustMMRA  with  the  pipeline  for  the  identification  of
single master miRNA regulators (MMRA)
We compared  the  results  of  ClustMMRA in  the  breast  cancer  study  with  those
obtained by applying to the same dataset the MMRA pipeline for the identification of
single master miRNA regulators. The goal is to investigate if the regulatory effect of a
cluster can be detected by studying the effect of individual miRNAs belonging to the
same cluster.  
We applied MMRA to the Curie dataset, using in each step the same thresholds
employed for ClustMMRA. If at least two miRNAs of a given cluster are included in
the  output  of  MMRA,  we  consider  this  cluster  as  detected  in  the  single-miRNA
pipeline. Interestingly, 4 out of 7 clusters detected by ClustMMRA (miR-199a/214,
miR-493/136, miR-512/373 and miR-450b/424) were not detected by MMRA. 
This  difference  between  the  output  of  the  two  pipelines  is  given  by  the  target
enrichment analysis in step (ii) and the network analysis in step (iii). In fact, the 4
clusters missing in the final output of MMRA are included in the output of step (i),
since they have at least 2 differentially expressed miRNA genes. They are filtered
out in step (ii) since no miRNA gene in these clusters, when analyzed individually,
reaches  a  significant  enrichment  of  signatures  genes  in  its  targets  for  a  certain
subtype.  This  observation  supports  the  hypothesis  that  co-clustered  miRNAs
participate in regulating the gene expression signature of a given cancer subtype
without necessarily having a high overlap in terms of common target genes.
2.2.3 Prioritization of miRNA clusters for functional validation in cell lines
Before experimental validation of the ClustMMRA output, prioritization of results was
performed. We considered the 5 clusters identified both in TCGA and Curie datasets.
For the  regulons associated to each cluster, the nodes present in both TCGA and
Curie datasets were kept, obtaining a network for each  regulon with size of about
100 nodes. Then, biological processes and pathways associated to these regulons
were identified through Fisher’s exact enrichment test, using MSigDB 47as reference
collection of signatures for pathways and biological functions. The  complete list of
MSigDB  pathways  resulting  from  this  analysis  (FDR  <  0.05)  is  reported  in
Supplementary Table S3. 
Overall, the network analysis shows a regulation of EMT, stemness and extracellular
matrix  by  clusters  miR-493/136,  miR-379/656  and  miR-199a/214.  Cluster  miR-
532/502 is predicted to regulate proliferation and the cell cycle transition from G to M
phases.  All  the  regulons have  been  found  associated  to  breast  cancer  specific
signatures, with clusters miR-493/136, miR-379/656 and miR-199a/214 sharing 9 of
them
(“SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP”,“FARMER_BREAST_C
ANCER_CLUSTER_4”,“TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOB
ULAR_NORMAL_DN”,“CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHY
MAL_DN”,“LANDIS_BREAST_CANCER_PROGRESSION_DN”,“LANDIS_ERBB2_B
REAST_TUMORS_324_DN”,“LIEN_BREAST_CARCINOMA_METAPLASTIC”,“TUR
ASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP”,“TURAS
HVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP”,“TURASH
VILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN”).  Invasive
and mesenchymal state signatures confirm the association of these clusters to the
basal-like subtype.  Other general processes were found enriched in the regulons of
these  clusters:  EMT  (including  the
“HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION” signature and multiple
GO  terms  related  to  the  extracellular  matrix),  stemness
(“BOQUEST_STEM_CELL_UP”,“LIM_MAMMARY_STEM_CELL_UP”,“IZADPANAH
_STEM_CELL_ADIPOSE_VS_BONE_DN”  signatures),  cell  cycle
(“IGLESIAS_E2F_TARGETS_UP”)  and  angiogenesis
(“GO_VASCULATURE_DEVELOPMENT”,“GO_CIRCULATORY_SYSTEM_DEVEL
OPMENT”). Finally, the regulon of cluster miR-532/502 was found enriched in some
breast  cancer  specific  signatures  clearly  linking  it  to  the  basal-like  subtype
(“SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP”,“FARMER_BREAST_CAN
CER_BASAL_VS_LULMINAL”  and  “POOLA_INVASIVE_BREAST_CANCER_UP”).
Also,  it  was  observed  to  be  strongly  associated  to  proliferation  signatures  (e.g.
“ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR”,“GO_MITOTIC_NUCL
EAR_DIVISION”,“GO_MITOTIC_CELL_CYCLE”,“GO_CHROMOSOME_SEGREGA
TION”,“GO_CELL_DIVISION”,“GO_CELL_CYCLE_PROCESS”,“CHANG_CYCLING
_GENES”). 
We focused on EMT regulation by miR-199a/214 as an interesting phenotype to
validate  in  basal-like  subtype.  MiR-199a/214  is  the  smallest  cluster  that  controls
EMT, in terms of miRNA genes. Considering the technical difficulty in producing the
over-expression  of  multiple  miRNAs  in  cell  lines,  this  was  chosen  as  the  best
candidate to study the combinatorial regulation by co-clustered miRNAs.
2.2.4 MiR-199a/miR-214 cluster is underexpressed in TNBC cells
Human  miR-199a/miR-214  cluster  is  encoded  by  a  large  non-coding  RNA  on
chromosome 1q24 which produces three mature miRNAs (hsa-miR-199a-5p, hsa-
miR-199a-3p and hsa-miR-214).  First,  we examined by  quantitative  RT-PCR the
expression of the individual mature miRNAs belonging to this cluster in T47D and
MDA-MB-231 cells, which are luminal A and TNBC cells respectively48. Results show
that  the  three  mature  miRNAs  encoded  by  the  miR-199a/miR-214  cluster  are
significantly underexpressed in MDA-MB-231 compared to T47D cells (Fig.3). 
2.2.5  Upregulation  of  miR-199a/miR-214  cluster  decreases  TNBC  cell
proliferation 
To  test  whether  the  deregulation  of  miR-199a/miR-214  cluster  was  sufficient  to
impact  TNBC  cells  phenotype,  MDA-MB-231  cells  were  treated  with  sense  (S)
oligonucleotides encoding for  all  the three miRNAs of the cluster (miR-214, miR-
199a-5p,  miR-199-3p)  or  scramble  negative  controls.  We  checked  the
overexpression of each miRNA of the cluster after transfection by RT-PCR analysis,
shown in Fig.4A-C. After confirming the upregulation of single miRNA or all three
miRNAs  of  the  cluster  in  MDA-MB-231,  we  analyzed  the  effect  of  miRNA
overexpression on proliferation: individual miRNAs, except miR-199a-3p, and entire
miR-199a/miR-214  cluster  overexpression  reduce  the  MDA-MB-231  cell  number
compared to scramble or untreated control (Fig. 5).
2.2.6  MiR-199a/miR-214  cluster  silencing  is  associated  with  EMT-like  and
invasive phenotype
According  to  bioinformatic  analysis,  miR-199a/miR-214  cluster  is  predicted  to
modulate  EMT genes  and  cell  invasion.  To  investigate  if  the  expression  of  this
cluster affects the molecular profile of the cells, we analyzed the expression levels of
EMT-related genes upon upregulation of a single miRNA of the cluster or the whole
cluster through S oligonucleotide treatment. We observed a reduction of EMT marker
genes  upon  both  individual  miRNAs  or  entire  miR-199a/miR-214  cluster
overexpression  (Fig.6),  as  demonstrated  by  the  increase expression  of  epithelial
markers E-cadherin and Beta-catenin and a decrease of the expression level of the
mesenchymal marker Slug.
Finally,  we  used  an  in  vitro culture  system developed  to  assess  mammary  cell
propagation in non-adherent, non-differentiated culture conditions and their ability to
form discrete clusters of cells termed mammospheres49. The ability of the cells to
form mammosphere could be considered also a marker of the stemness of the cell
population49. The formation of such spheroids increases with EMT induction (PMID:
18485877). Our experiments on MDA-MB-231 cells show that the expression of miR-
199a/miR-214 cluster is sufficient to compromise mammosphere formation efficiency
(Fig.7).  In  fact,  when we overexpressed either  miR-214 or  miR-199a-5p or  miR-
199a-3p  and  the  three  miRNAs  together,  we  observed  a  decrease  efficacy  in
mammosphere formation in respect to untreated cells.
3. Discussion
Over the last  two decades there has been an explosion of  research focused on
miRNAs involvement in cancer initiation and progression, pointing out the potential of
these small RNAs as biomarkers for diagnosis, prognosis and response to treatment.
However,  the  majority  of  computational  and  experimental  approaches  for  the
identification of master miRNA regulators involved in cancer onset and subtyping are
typically designed to detect the regulatory effect of a single miRNA. This can be a
limitation in identifying regulation by multiple miRNA species acting cooperatively on
cellular pathways and pathological changes.
The computational pipeline here described, ClustMMRA, was specifically designed
to  search for  genomically  clustered miRNAs potentially  driving  cancer  subtyping.
ClustMMRA  provides  a  computational  framework  to  systematically  investigate
polycistronic  miRNA transcripts  involved in  cancer  subtyping or  possibly  in  other
biological contexts. In practice, the use of ClustMMRA can be generalized in order to
study  other  classes  of  cooperatively  acting  miRNAs  than  the  case  of  genomic
clusters, such as co-expressed miRNAs from different genomic locations.
In our study, ClustMMRA was applied to search for oncogenic / tumour suppressor
polycistronic miRNAs driving breast cancer subtypes, pointing out five novel miRNA
clusters  whose  regulatory  effect  is  potentially  associated  to  the  triple  negative
subtype phenotype. Among them, the miR-199/miR-214 is identified as acting on
EMT  in  TNBC  subtype.  Our  computational  and  experimental  validation  of  the
regulatory effect of miR-199/miR-214 show that the down-regulation of this genomic
cluster is associated to appearance of EMT-like phenotype in the TNBC cells. The
upregulation  of  individual  miRNAs  belonging  to  the  cluster  or  the  entire  cluster
decreases the expression of a marker of mesenchymal phenotype (i.e., Slug) and
increases the expression of epithelial markers (E-cadherin and Beta-catenin). These
changes  towards  an  epithelial  phenotype,  obtained  by  overexpression  on  miR-
199/miR-214 cluster, diminished the capability of the stem population of MDA-MB-
231 lineage of forming mammospheres in suspension. The presence of cancer stem
cells has been linked to poor cancer patient survival, as those tumors with a high
percentage of cancer stem cells are capable of migrating, invading and colonizing
surrounding tissues, surviving in suspension, and creating a secondary tumor50. Our
results suggest that this cluster of miRNAs is possibly involved in the maintenance of
more aggressive phenotype of  breast  cancer,  by controlling the stemness of the
population,  regulating EMT target  genes,  and cell  proliferation.  Finally,  our  study
supports a the hypothesis of miRNA cooperativity from a polycistronic transcript as a
possible mechanism of jointly targetting to act on molecular pathways involved in
cancer malignancy and subtyping. More accurate measurements and quantitative
study might improve the understanding of this cooperative effects.
4. Methods
4.1 MiRNA cluster annotation
The genomic locations of miRNAs were retreived from  miRBase v1851.  Similar to
previous  studies52,53,  co-clustered  miRNAs  are  defined  as  miRNA genes  located
within 10 Kb of distance on the same chromosome and in the same strand. 
4.2 Datasets preprocessing
Breast cancer (BRCA) RNA-seq and miRNA-seq Level 3 expression profiles were
downloaded from The Cancer Genome Atlas (TCGA) in January 2016. Only those
primary tumors profiled for both mRNA and miRNA expression were included in the
analysis, obtaining a total of 397 samples. Two expression matrices (one for mRNAs
and the second for miRNAs) were normalized obtaining the paired mRNA/miRNA
expression dataset here referred to as TCGA. The Curie dataset was generated with
microarray technologies (Agilent miRNA microarray kit V3 for miRNAs and Affymetrix
U133plus2 for mRNA) and pre-processed following the procedure described in54.
4.2 Definition of a gene signature for each breast cancer subtype
The  ClustMMRA  pipeline  requires  as  input  a  gene  signature  for  each  disease
subtype.  Available  signatures  for  breast  cancer  subtypes,  such as  the  PAM5055,
were not applicable here due to their limited size in terms of number of genes. We
thus defined the signatures for our breast cancer study using the approach proposed
in38. The Curie dataset was used for signature construction, while the TCGA dataset
was employed for signature validation. Differential gene expression for each subtype
vs. all the other samples was computed by Student’s t-test and log fold change cutoff
(t-test adjusted p-value < 0.05 and absolute(log fold change) > 0.5). Moreover, to
increase the predictive power of the constructed signatures, those genes associated
to more than one class according to the previous criteria,  or having a difference
between the first and second highest  absolute(log fold changes) lower than 0.2 were
discarded. The choice of thresholds was optimized to maximize the gene association
to  a  unique  subtype  and  the  number  of  genes  included  in  each  signature  (on
average 117 genes per signature). For each subtype, two separated signatures were
defined ("down"  and "up"),  based on the sign of  the  expression change of  their
genes. The signatures constructed in this way are available in Supplementary Table
S4. The  reliability  of  these  signatures  were  tested  in  two  ways.  First,  their
classification performances were validated on TCGA data. We classified the TCGA
samples using our signatures with the Nearest Template Prediction (NTP) method56,
as done in57,58. Only 44 out of 397 (11%) samples resulted to be misclassified. Then,
the significance of the intersection between our  signatures and publicly  available
ones was evaluated by a Fisher’s exact test. The signatures used for this test were
obtained  from  MSigDB47 plus  a  specific  one  derived  from59.  The  proliferation
signatures were added to test the basal-like subtype, known to be associated to a
strong  proliferative  signal.  Highly  significant  p-values  were  obtained  for  the
intersection between our newly defined signatures and previously published ones for
the  same  breast  cancer  subtypes.  The  above  results  confirm  the  classification
performances and reliability of the breast cancer signatures here constructed.
4.3 Cell culture and miRNA modulation 
For in vitro studies, we used two human BC epithelial cell lines: T47D and MDA-MB-
231 cells (ICLC-Biologic Bank and Cell Factory, Italy). These cell lines were chosen
as they represent a model of luminal A and TNBC cell lines, respectively48. Following
the manufacturer’s recommendation, we maintained the cell lines within a humidified
atmosphere containing 5% CO2 at 37 °C in DMEM (for T47D cell line) or advanced
DMEM (for MDA-MB-231 cell line) cell culture medium (Gibco, Life Technologies),
with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, 2mM glutamine (all
from Lonza, Euroclone). Dulbecco Phosphate-Buffered Saline (D-PBS), trypsin, and
all the media additives were obtained by Lonza (Euroclone).
The sense (S) oligonucleotide sequence of each miRNA of the cluster has been
designed  following  the  sequences  indicated  in  miRbase  database51.  S
oligonucleotides were purchased from Sigma.
To  obtain  the  upregulation  of  each  miRNA,  S  oligonucleotides,  resuspended  in
water, were added three times a day for 3 days directly to the culture medium of the
cells  (<50% confluency)  at  a  final  concentration  of  100nM/day60.  The  cells  were
collected  24,48  or  72h  of  treatment  and  different  assays  were  performed
(proliferation, mammosphere formation and real time-PCR analysis of miRNAs and
EMT genes).
4.3 Proliferation assay
Tumor  cell  proliferation  was  assessed  by  following  the  protocol  described  in61.
Briefly, cells were seeded at a confluency of 80000 cells/w in 24 well plates.  The
cells  were  added  daily  with  100nM  final  concentration  of  S  miR-214,  -199a-3p,
-199a-5p.  The cells were collected and counted at 24,48 or  72h of  treatment.  A
graphic representation of the cell counts was obtained by plotting the number of the
total cells at each time point. Experiments were performed three times in triplicate (n
=  9). 
4.5 Mammospheres preparation
After  miRNA treatment  cells  were  collected  and  seeded  in  non  adherent  plastic
plates (100 cells/ml) in DMEM:F12 (1:1) added with 1% penicillin-streptomycin, 2mM
glutamine, 1% Hepes, 10ng/ml bFGF, 20ng/ml B27, 20ng/ml EGF, as described in62.
Pictures were taken after 10 days of culture in suspension.
4.6 RNA isolation, reverse transcription and RT-PCR analysis
Total  RNA  was  isolated  using  TRIzol  reagent  (Life  Technologies)  following  the
manufacturer’s  recommendations.  To  obtain  cDNA  from  total  RNA   for  gene
expression analysis, two micrograms of total RNA were reverse transcribed using
oligo dT primers in combination with High Capacity cDNA Reverse Transcription kit
(Applied Biosystem), following the manufacturer’s protocol.
For  miRNA analysis,  one microgram of  total  RNA was reverse transcribed using
MystiCq  microRNA  cDNA  synthesis  kit  (Sigma),  following  the  manufacturer’s
protocol, in order to reverse transcribe polyA-tailed miRNA into cDNA.
RT-PCR analysis was performed using Power Up Sybr Green Master mix (Applied
Biosystem, Life Technologies) in an Eco RT-PCR machine (Illumina). All the primers
for  human mRNA and miRNA amplification  were  home-made and are described
below (Table xx). miRNA amplification was performed using primers designed on the
mature miRNA sequence taken from miRbase  v1851. HPRT and miR-103-3p were
used  as  an  internal  control  for  gene  expression  and  miRNA  profile  analysis,
respectively. Primers used are reported in Supp FileXXX
The relative expression of miRNAs and genes was calculated for both T47D and
MDA-MB-231 cell lines with the 2(-ΔΔCT) method63. Experiments were performed three
times in triplicate (n = 9). A t test was calculated.
5. Figures
Figure  1.  Schematic  representation  of  the  Clustered  microRNA  Master
Regulator Analysis (ClustMMRA) workflow. The schema reports the data required
as initial  input, the four analytical  steps with the respective outputs, and the final
output of the pipeline.
Figure 2. Pathways controlled by the deregulated miRNA clusters. A summary
of the main biological functions controlled by the different miRNA clusters is here
reported. Y-axis of the radarplot corresponds to the sum of the absolute log(p-value)
of all  the pathways associated to a given function. A,B,C,D correspond to  miR-
199a/214, miR-493/136, miR-379/656 and  miR-532/502, respectively.
Fig.3 RT-PCR analysis of miRNA expression in T47D vs MDA-MB-231. 
T47D (in white) and MDA-MB-231 (in grey) were analyzed for the expression of miR-
214 (A, p-value<0.011), miR-199a-5p (B, p-value<0.003) and miR-199a-3p (C, p-
value<0.03). 2^-DDCt method was used for evaluating the expression level of each
miRNA. Average±sd of three independent experiments for each cell line are shown.
T-test p-value<0.01(**), <0.05(*).
Fig.4 Mirna modulation in MDA-MB-231 cells.
MDA-MB-231 cells were treated for 48 hours with 100nM sense (S) oligonucleotide
encoding for miR-214, miR-199a-5p, miR-199a-3p or miRNA cluster, respectively.
The expression levels of miR-214 (A), miR-199a-5p (B) and miR-199a-3p (C) were
evaluated by RT-PCR analysis comparing miRNA-treated cells vs untreated cells.
Average±sd of three independent experiments for each cell line are shown. T-test p-
value<0.01(**), <0.05(*).
Fig.5  In  vitro  analysis  of  miRNA  modulation  effect  on  MDA-MB-231  cells
proliferation.
MDA-MB-231  cells  were  treated  for  24,48,72  hours  (h)  with  sense  (S)
oligonucleotide encoding for miRNA cluster or single miRNA (miR-214, miR-199a-
5p, miR-199a-3p) or a scramble miRNA. The effect of miRNA modulation on cell
proliferation is shown. Average±sd of three independent experiments for each cell
line are shown. T-test p-value<0.001(***),<0.01(**), <0.05(*).
Fig.6 Effect of miRNA modulation on EMT marker genes. 
MiRNA  modulated  MDA-MB-231  cells  were  used  for  RT-PCR  analysis  of  EMT
marker genes. RT-PCR analysis shows the effect of single miRNA or miRNA cluster
modulation vs scramble oligonucleotide treated cells on E-cadherin (A), Beta-catenin
(B) and Slug (C). Average±sd of three independent experiments for each cell line are
shown. T-test p-value<0.01(**), <0.05(*).
Fig.7 Effect of miRNA modulation on mammosphere (MM) formation ability. 
MiRNA-modulated  MDA-MB-231  were  used  for  MM  assay.  Pictures  of  miRNA
cluster-treated vs scramble oligonucleotide-treated cells were taken after 10 days of
MM formation.
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